Tags

Type your tag names separated by a space and hit enter

The effect of 24 months recombinant human growth hormone (rh-GH) on LDL cholesterol, triglyceride-rich lipoproteins and apo [a] in hypopituitary adults previously treated with conventional replacement therapy.
Growth Horm IGF Res. 1999 Jun; 9(3):165-73.GH

Abstract

Hypopituitary adults receiving conventional hormone replacement therapy are reported to have increased cardiovascular mortality. Previous studies indicate that these patients have several abnormalities in lipoprotein metabolism, including reduced low density lipoprotein (LDL) uptake and impaired metabolism of triglyceride-rich lipoproteins. The effects of 24 months of 0.21 IU/kg per week recombinant growth hormone (rh-GH) on the lipoprotein profiles of 22 GH-deficient adults were studied. Samples were collected after a 12-h fast at baseline and 24 months. Total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol, LDL cholesterol, apolipoprotein (apo) A, apo B and apo [a] were determined by routine laboratory methods. LDL particle size was determined by non-denaturing gradient gel electrophoresis. Visceral adiposity was determined by dual energy X-ray absorptiometry (DEXA). Insulin sensitivity was measured in a subset of 17 subjects using a two-stage hyperinsulinaemic-euglycaemic clamp. Significant reductions were observed in total cholesterol (5.3 +/- 0. 17 vs 4.9 +/- 0.23 mmol/l;P<0.05) and LDL cholesterol (3.4 +/- 0.17 vs 2.9 +/- 0.17 mmol/l; P<0.001) at 24 months when compared to baseline. No significant changes were observed in triglyceride level, HDL cholesterol level, apo B, apo A and LDL size. A significant increase in apo [a] [160 (96-416) vs 204 (127-534) U/l;P<0.05] was observed which appeared to be dose-dependent. Visceral adiposity was reduced significantly. Insulin sensitivity did not alter significantly. Replacement for 24 months with rh-GH has a differential effect on the lipid profile with a decrease in LDL, but little effect upon the metabolism of triglyceride-rich lipoproteins, manifested by unchanged triglyceride, HDL cholesterol levels and LDL size, despite the reduction in visceral adiposity. Conversely, apo [a], an independent risk factor for cardiovascular disease was increased. The ultimate effect of GH therapy upon cardiovascular mortality remains to be determined and may be dose-related.

Authors+Show Affiliations

University of Melbourne Department of Medicine, St Vincent's Hospital, Fitzroy, Victoria, 3065, Australia.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10502452

Citation

O'Neal, D N., et al. "The Effect of 24 Months Recombinant Human Growth Hormone (rh-GH) On LDL Cholesterol, Triglyceride-rich Lipoproteins and Apo [a] in Hypopituitary Adults Previously Treated With Conventional Replacement Therapy." Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society, vol. 9, no. 3, 1999, pp. 165-73.
O'Neal DN, Hew FL, Best JD, et al. The effect of 24 months recombinant human growth hormone (rh-GH) on LDL cholesterol, triglyceride-rich lipoproteins and apo [a] in hypopituitary adults previously treated with conventional replacement therapy. Growth Horm IGF Res. 1999;9(3):165-73.
O'Neal, D. N., Hew, F. L., Best, J. D., & Alford, F. (1999). The effect of 24 months recombinant human growth hormone (rh-GH) on LDL cholesterol, triglyceride-rich lipoproteins and apo [a] in hypopituitary adults previously treated with conventional replacement therapy. Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society, 9(3), 165-73.
O'Neal DN, et al. The Effect of 24 Months Recombinant Human Growth Hormone (rh-GH) On LDL Cholesterol, Triglyceride-rich Lipoproteins and Apo [a] in Hypopituitary Adults Previously Treated With Conventional Replacement Therapy. Growth Horm IGF Res. 1999;9(3):165-73. PubMed PMID: 10502452.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of 24 months recombinant human growth hormone (rh-GH) on LDL cholesterol, triglyceride-rich lipoproteins and apo [a] in hypopituitary adults previously treated with conventional replacement therapy. AU - O'Neal,D N, AU - Hew,F L, AU - Best,J D, AU - Alford,F, PY - 1999/9/30/pubmed PY - 1999/9/30/medline PY - 1999/9/30/entrez SP - 165 EP - 73 JF - Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society JO - Growth Horm IGF Res VL - 9 IS - 3 N2 - Hypopituitary adults receiving conventional hormone replacement therapy are reported to have increased cardiovascular mortality. Previous studies indicate that these patients have several abnormalities in lipoprotein metabolism, including reduced low density lipoprotein (LDL) uptake and impaired metabolism of triglyceride-rich lipoproteins. The effects of 24 months of 0.21 IU/kg per week recombinant growth hormone (rh-GH) on the lipoprotein profiles of 22 GH-deficient adults were studied. Samples were collected after a 12-h fast at baseline and 24 months. Total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol, LDL cholesterol, apolipoprotein (apo) A, apo B and apo [a] were determined by routine laboratory methods. LDL particle size was determined by non-denaturing gradient gel electrophoresis. Visceral adiposity was determined by dual energy X-ray absorptiometry (DEXA). Insulin sensitivity was measured in a subset of 17 subjects using a two-stage hyperinsulinaemic-euglycaemic clamp. Significant reductions were observed in total cholesterol (5.3 +/- 0. 17 vs 4.9 +/- 0.23 mmol/l;P<0.05) and LDL cholesterol (3.4 +/- 0.17 vs 2.9 +/- 0.17 mmol/l; P<0.001) at 24 months when compared to baseline. No significant changes were observed in triglyceride level, HDL cholesterol level, apo B, apo A and LDL size. A significant increase in apo [a] [160 (96-416) vs 204 (127-534) U/l;P<0.05] was observed which appeared to be dose-dependent. Visceral adiposity was reduced significantly. Insulin sensitivity did not alter significantly. Replacement for 24 months with rh-GH has a differential effect on the lipid profile with a decrease in LDL, but little effect upon the metabolism of triglyceride-rich lipoproteins, manifested by unchanged triglyceride, HDL cholesterol levels and LDL size, despite the reduction in visceral adiposity. Conversely, apo [a], an independent risk factor for cardiovascular disease was increased. The ultimate effect of GH therapy upon cardiovascular mortality remains to be determined and may be dose-related. SN - 1096-6374 UR - https://www.unboundmedicine.com/medline/citation/10502452/The_effect_of_24_months_recombinant_human_growth_hormone__rh_GH__on_LDL_cholesterol_triglyceride_rich_lipoproteins_and_apo_[a]_in_hypopituitary_adults_previously_treated_with_conventional_replacement_therapy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1096-6374(99)90102-8 DB - PRIME DP - Unbound Medicine ER -